Tandem Diabetes Care 

$44.7
60
+$0.88+2.01% Friday 20:00

統計

當日最高
44.89
當日最低
43.58
52週最高
53.69
52週最低
13.82
成交量
832,812
平均成交量
1,987,399
市值
2.93B
市盈率
-21.39
股息收益率
-
股息
-

即將到來

收益

30Oct確認
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
-1.92
-1.37
-0.82
-0.27
預期每股收益
-0.411666
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 TNDM 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

55.55$平均價格目標
最高估價為 $75。
來自過去 6 個月內的 11 個評級。這不是投資建議。
買入
91%
持有
9%
賣出
0%

關於

Health Technology
Medical Specialties
Manufacturing
Surgical and Medical Instrument Manufacturing
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Show more...
首席執行官
John Sheridan
員工
2400
國家
US
ISIN
US8753722037
WKN
000A2H5BX

上市公司